Skip to main content

Sudan Loganathan

Stock Analyst at Stephens

Total Price Targets
5
Stocks Covered
5
Sectors
Healthcare
Most Recent
Dec 11, 2025

Notable Calls (Last 12 Months)

Most Bullish

  • ARVN+80.6%
    Arvinas, Inc.
    $14.00 targetSep 18, 2025
  • CCCC+68.1%
    C4 Therapeutics, Inc.
    $6.00 targetSep 15, 2025
  • KYMR+22.4%
    Kymera Therapeutics, Inc.
    $110.00 targetDec 11, 2025

Most Bearish

  • KYMR+22.4%
    Kymera Therapeutics, Inc.
    $110.00 targetDec 11, 2025
  • CCCC+68.1%
    C4 Therapeutics, Inc.
    $6.00 targetSep 15, 2025
  • ARVN+80.6%
    Arvinas, Inc.
    $14.00 targetSep 18, 2025

Stocks Covered by Sudan Loganathan

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
KYMRKymera Therapeutics, Inc.$110.00$81.54+34.9%1Dec 11, 2025
ARVNArvinas, Inc.$14.00$10.55+32.7%1Sep 18, 2025
CCCCC4 Therapeutics, Inc.$6.00$2.90+106.5%1Sep 15, 2025
EXELExelixis, Inc.$23.00$43.81-47.5%1Oct 14, 2024
INOInovio Pharmaceuticals, Inc.$20.00$1.12+1685.7%1May 13, 2024

Recent Activity

  • Dec 11, 2025— Set$110.00price target onKYMR(Kymera Therapeutics, Inc.)
  • Sep 18, 2025— Set$14.00price target onARVN(Arvinas, Inc.)
  • Sep 15, 2025— Set$6.00price target onCCCC(C4 Therapeutics, Inc.)
  • Oct 14, 2024— Set$23.00price target onEXEL(Exelixis, Inc.)
  • May 13, 2024— Set$20.00price target onINO(Inovio Pharmaceuticals, Inc.)

Frequently Asked Questions

Who is Sudan Loganathan?

Sudan Loganathan is a stock analyst at Stephens covering 5 stocks primarily in Healthcare. They have issued 5 price targets since May 13, 2024.

What stocks does Sudan Loganathan cover?

Sudan Loganathan currently covers 5 stocks, including KYMR, ARVN, CCCC, EXEL, INO.

What is Sudan Loganathan's latest price target?

Sudan Loganathan's most recent price target was $110.00 on KYMR (Kymera Therapeutics, Inc.), set on Dec 11, 2025.

What is Sudan Loganathan's highest price target?

Sudan Loganathan's highest issued price target is $110.00 on KYMR, set on Dec 11, 2025.

Coverage based on publicly published price targets. Not investment advice.